Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
3.600
+0.100 (2.86%)
At close: Jan 17, 2025, 4:00 PM
3.610
+0.010 (0.28%)
After-hours: Jan 17, 2025, 5:03 PM EST
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $416.00K in the quarter ending September 30, 2024, a decrease of -99.59%. This brings the company's revenue in the last twelve months to $196.49M, down -33.22% year-over-year. In the year 2023, Amylyx Pharmaceuticals had annual revenue of $380.79M with 1,612.94% growth.
Revenue (ttm)
$196.49M
Revenue Growth
-33.22%
P/S Ratio
1.24
Revenue / Employee
$511,680
Employees
384
Market Cap
245.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
Dec 31, 2019 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
AMLX News
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 7 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - Accesswire
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - Accesswire
- 10 days ago - Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Business Wire
- 11 days ago - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
- 12 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - Accesswire
- 13 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire